FDA Inter-Center Ad Group Launches Prior To Departure Of Chief Counsel Troy
This article was originally published in The Pink Sheet Daily
Executive Summary
The Promotion Steering Committee is expected to develop guidance documents that bring transparency to FDA’s oversight of product advertising and reflect common standards for promotion across product areas, Troy says.
You may also be interested in...
FDA Acting Chief Counsel To Be Masoudi
Dan Troy will leave agency Nov. 24 after three years which included major Waxman/Hatch reforms and reconsideration of First Amendment issues. Newly appointed deputy chief counsel Masoudi will succeed Troy until a permanent chief counsel is selected by HHS’ Azar.
"Promotion Steering Committee" In Planning Stage, FDA Ad Division Head Says
The group will include senior officials from the drug and biologics review centers and reps from the chief counsel's and commissioner's offices, CDER ad division director Abrams says. CDER has issued eight warning letters this year; omission of risk information and unproven claims are most common violations.
FDA To Create Inter-Center Advertising Policy Group
The group will "rationalize" FDA policy on advertising regulation and coordinate enforcement efforts between the centers. FDA plans to develop guidance relating to outdoor advertising, comparative claims and implied claims later this year.